A novel L1CAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing

Area of Science:

• Molecular Biology
• Cell Biology
• Oncology

Background:

• Angiogenesis, the formation of new blood vessels, is crucial for development and disease but involves incompletely understood molecular mechanisms.
• Endothelial cells (ECs) are key players in angiogenesis, responding to various signaling pathways.

Purpose of the Study:

• To identify novel regulators of angiogenesis originating from endothelial cells.
• To investigate the function and clinical relevance of a newly identified L1CAM isoform in angiogenesis and ovarian cancer.

Main Methods:

• Analysis of L1CAM splicing in endothelial cells using the splicing factor NOVA2.
• Characterization of the angiogenic properties of the soluble L1-ΔTM isoform in vitro and in vivo.
• Correlation of NOVA2 and L1-ΔTM expression with tumor vascularization and patient outcomes in ovarian cancer samples.

Main Results:

• A novel L1CAM isoform, L1-ΔTM, lacking the transmembrane domain, is generated in ECs through NOVA2-mediated alternative splicing.
• Soluble L1-ΔTM exhibits potent autocrine and paracrine angiogenic activity, dependent on fibroblast growth factor receptor-1 signaling.
• NOVA2 and L1-ΔTM are overexpressed in ovarian cancer vasculature, with L1-ΔTM levels correlating with tumor vascular density.
• High NOVA2 expression in patients is associated with poorer ovarian cancer outcomes.

Conclusions:

• L1-ΔTM is a novel, EC-derived angiogenic factor with significant implications in tumor angiogenesis, particularly in ovarian cancer.
• The NOVA2-L1-ΔTM axis represents a potential therapeutic target for anti-angiogenic strategies in cancer treatment.